BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission

Blood. 1990 Jun 15;75(12):2282-5.

Abstract

Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to BAVC conditioning regimen followed by unpurged ABMT. Transplant was done after a median of 2 months from II CR (range, 1 to 13). Median first remission (I CR) duration was 16 months (range, 1-35). Conditioning regimen was well tolerated, with no major extra-medullary toxicity. One patient died during aplasia from fungal sepsis. Of the 20 evaluable patients, nine relapsed after a median time of 6 months (range, 2 to 18). Eleven patients are in continuous complete remission (CCR) after a median follow-up of 40 months (range, 24 to 63). The duration of II CR has exceeded the duration of I CR in all patients in CCR. Projected probability of disease-free survival is 52% at 63 months.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amsacrine / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Transplantation*
  • Carmustine / therapeutic use
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / surgery
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Survival Analysis

Substances

  • Amsacrine
  • Cytarabine
  • Etoposide
  • Carmustine